No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Positive 52-Week, Ph 3 Results for Celltrion’s Aflibercept Biosimilar
On 23 September 2024, Celltrion announced that it presented the 52-week results of its Phase 3 trial of Eydenzelt™ (CT-P42), biosimilar to Regeneron’s Eylea® (aflibercept), at the European Society of Retina Specialists (EURETINA) conference held from 19-22 September...